SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Parving, H.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parving, H.-H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Diabetic Kidney Problems
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Editorial

Blockade of the renin-angiotensin-aldosterone system and renal protection in diabetes mellitus

Hans-Henrik Parving

Steno Diabetes Center Niels Steensens Vej 2 DK-2820 Gentofte Denmark, hhparving{at}dadlnet.dk

Key Words: hypertension • diabetes • renin-angiotensin-aldosterone system • renal protection • ACE inhibitors

References

  • Parving H-H., sterby R., Anderson PW, Hsueh WA Diabetic nephropathy. In: Brenner BM, editor. The Kidney. 5th ed. Philadelphia: Saunders, 1996:1864-1892.
  • Parving H-H. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 1998; 41:745-759.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hostetter TH, Rennke HG, Brenner BM The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 72:375-380.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Zatz R., Dunn BR, Meyer TW, Anderson S., Rennke HG, Brenner BM Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77:1925-1930.[Web of Science][Medline] [Order article via Infotrieve]
  • Deinum J., Tarnow L., van Gool JM, et al. Plasma renin and prorenin and renin gene variation in patients with insulin-dependent diabetes mellitus and nephropathy. Nephrol Dial Transplant 1999; 14:1904-1911.1.[Abstract/Free Full Text]
  • De'Oliveira JM, Price DA, Fisher NDL, et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int 1997; 52:771-777.[Web of Science][Medline] [Order article via Infotrieve]
  • Wagner J., Gehlen F., Ciechanowicz A., Ritz E. Angiotensin II receptor type 1 gene expression in human glomerulonephritis and diabetes mellitus. J Am Soc Nephrol 1999; 10:545-551.[Abstract/Free Full Text]
  • Tarnow L., Gluud C., Parving H-H. Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant 1998; 13:1125-1130.[Free Full Text]
  • Parving H-H., Jacobsen P., Tarnow L. et al. Effect of deletion polymorphism of angiotensin-converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin-converting enzyme: observational follow up study. Br Med J 1996; 313:591-594.[Abstract/Free Full Text]
  • The Euclid Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349:1787-1792.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ravid M., Brosh D., Levi Z., Bar-Dayan Y., Ravid D., Rachmani R. Use of enalapril to attennuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. Ann Intern Med 1998; 128:982-988.[Abstract/Free Full Text]
  • Marre M., Leblanc H., Suarez L., Guyenne T-T., Ménard J., Passa P. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J 1987; 294:1448-1452.[Abstract/Free Full Text]
  • Mogensen CE, Keane WF, Bennett PH et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346:1080-1084.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mathiesen ER, Hommel E., Hansen HP, Smidt UM, Parving H-H. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. Br Med J 1999; 319:24-25.[Free Full Text]
  • Ravid M., Savin H., Jutrin I., Bental T., Katz B., Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118:577-581. 16. Hommel E., Parving H-H., Mathiesen ER, Edsberg B., Nielsen MD, Giese J. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J 1986; 293:466-470.
  • Björck S., Nyberg G., Mulec H., Granerus G., Herlitz H., Aurell M. Beneficial effect of angiotensin-converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 1986; 293:471-474.[Web of Science][Medline] [Order article via Infotrieve]
  • Björck S., Mulec H., Johnsen SA, Nordén G., Aurell M. Renal protective effect of enalapril in diabetic nephropathy. Br Med J 1992; 304:339-343.[Web of Science][Medline] [Order article via Infotrieve]
  • Lewis E., Hunsicker L., Bain R., Rhode R. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-1462. 20. Andersen S., Tarnow L., Rossing P., Hansen BV, Parving H-H. Renoprotective effects of angiotensin II receptor blokade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; In press.

Journal of Renin-Angiotensin-Aldosterone System, Vol. 1, No. 1, 30-31 (2000)
DOI: 10.3317/jraas.2000.006


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Parving, H.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parving, H.-H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Diabetic Kidney Problems
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement